UK campaign for access to treatments and support for those with spinal muscular atrophy
A comprehensive guide to what SMA is
and what to be aware of.
Everything you need to know about treatments available now and future.
SMA experts have developed and published consensus guidelines on SMA care.
Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and…
SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza…
This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could…
The Medicines and Health Products Regulatory Agency (MHRA) has given marketing authorisation to Evrysdi®▼(risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in individuals…
In a groundbreaking discovery, researchers have identified a previously unknown mechanism that contributes to the progressive degeneration of motor neurons in spinal muscular atrophy (SMA).…
Today is ‘Worldwide Stop The Pressure Day’ The objective this day is to increase awareness about pressure injury prevention and to educate the public on…
Despite their already reading treatments available the world of science never stops. They continues to be active trials and development on a number of new treatments. Below is the current position to the best of our knowledge of each, and this will be updated as we receive further updates
